Doxycycline Post-Exposure Prophylaxis for Bacterial Sexually Transmitted Infections: The Current Landscape and Future Directions.
Humans
Doxycycline
/ therapeutic use
Anti-Bacterial Agents
/ therapeutic use
Male
Post-Exposure Prophylaxis
/ methods
Sexually Transmitted Diseases, Bacterial
/ prevention & control
Homosexuality, Male
Female
Chlamydia Infections
/ prevention & control
Gonorrhea
/ prevention & control
Chlamydia trachomatis
/ drug effects
Doxycycline post-exposure prophylaxis
Narrative review
Sexually transmitted infection prevention
Journal
Current HIV/AIDS reports
ISSN: 1548-3576
Titre abrégé: Curr HIV/AIDS Rep
Pays: United States
ID NLM: 101235661
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
accepted:
14
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
The incidence of bacterial sexually transmitted infections (STI) continues to rise particularly among men who have sex with men (MSM). Doxycycline post-exposure prophylaxis (doxy-PEP) has emerged as a promising biomedical prevention strategy. This review aims to summarize the results of recent studies, highlight the current normative guidance on the use of doxy-PEP, and discuss remaining questions. In the past decade, there have been four randomized controlled trials and three real-world analyses of doxy-PEP, which consistently demonstrated a reduction in Chlamydia trachomatis and Treponema pallidum infections among MSM. Questions remain regarding the efficacy of doxy-PEP for Neisseria gonorrhoeae infection and among cisgender women. Possible detrimental impacts include an increase in antimicrobial resistance as well as alterations to the gut microbiome Doxy-PEP is an effective strategy for preventing Chlamydia trachomatis and Treponema pallidum among MSM. Further work is needed to investigate the benefits among other populations, as well as to monitor for adverse effects.
Identifiants
pubmed: 39476167
doi: 10.1007/s11904-024-00709-w
pii: 10.1007/s11904-024-00709-w
doi:
Substances chimiques
Doxycycline
N12000U13O
Anti-Bacterial Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1Subventions
Organisme : National Institute of Allergy and Infectious Diseases,United States
ID : K23AI182453
Organisme : Harvard University Centers For AIDS Research
ID : R24AI067039
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
World Health Organization. Sexually Transmitted Infections (STIs). https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-(stis ) Updated July 2023. Accessed August 17, 2023.
Centers for Disease Control and Prevention, Sexually Transmitted Infections, Surveillance. 2022. Last Reviewed January 30, 2024. https://www.cdc.gov/std/statistics/2022/default.htm Accessed April 29, 2024.
Centers for Disease Control and Prevention, Sexually Transmitted Infections, Surveillance. 2022. Last updated January 30, 2024. https://www.cdc.gov/std/statistics/2022/figures.htm Accessed June 19, 2024.
McDonald R, O’Callaghan K, Torrone E, Barbee L, Grey J, Jackson D, et al. Vital signs: missed opportunities for preventing congenital syphilis - United States, 2022. MMWR Morb Mortal Wkly Rep. 2023;72(46):1269–74.
pubmed: 37971936
doi: 10.15585/mmwr.mm7246e1
Tsevat DG, Wiesenfeld HC, Parks C, Peipert JF. Sexually transmitted diseases and infertility. Am J Obstet Gynecol. 2017;216(1):1–9.
pubmed: 28007229
doi: 10.1016/j.ajog.2016.08.008
Moodley P, Wilkinson D, Connolly C, Moodley J, Sturm AW. Trichomonas Vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis. 2002;34(4):519–22.
pubmed: 11797180
doi: 10.1086/338399
Dolange V, Churchward CP, Christodoulides M, Snyder LAS. The growing threat of Gonococcal blindness. Antibiot (Basel). 2018;7(3).
Jarvis GA, Chang TL. Modulation of HIV transmission by Neisseria gonorrhoeae: molecular and immunological aspects. Curr HIV Res. 2012;10(3):211–7.
pubmed: 22384840
doi: 10.2174/157016212800618138
Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004;2(1):33–42.
pubmed: 15035007
doi: 10.1038/nrmicro794
Chesson HW, Pinkerton SD. Sexually transmitted diseases and the increased risk for HIV transmission: implications for cost-effectiveness analyses of sexually transmitted disease prevention interventions. J Acquir Immune Defic Syndr. 2000;24(1):48–56.
pubmed: 10877495
doi: 10.1097/00042560-200005010-00009
Zetola NM, Bernstein KT, Wong E, Louie B, Klausner JD. Exploring the relationship between sexually transmitted diseases and HIV acquisition by using different study designs. J Acquir Immune Defic Syndr. 2009;50(5):546–51.
pubmed: 19367993
doi: 10.1097/QAI.0b013e318195bd2b
Cohen MS, Council OD, Chen JS. Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy. J Int AIDS Soc. 2019;22(Suppl Suppl 6):e25355.
pubmed: 31468737
doi: 10.1002/jia2.25355
Jones J, Weiss K, Mermin J, Dietz P, Rosenberg ES, Gift TL, et al. Proportion of Incident Human Immunodeficiency Virus cases among men who have sex with men attributable to Gonorrhea and Chlamydia: a modeling analysis. Sex Transm Dis. 2019;46(6):357–63.
pubmed: 31095100
doi: 10.1097/OLQ.0000000000000980
Singh AE, Romanowski B. Syphilis: review with emphasis on clinical, epidemiologic, and some biologic features. Clin Microbiol Rev. 1999;12(2):187–209.
pubmed: 10194456
doi: 10.1128/CMR.12.2.187
Thomas JC, Tucker MJ. The development and use of the concept of a sexually transmitted disease core. J Infect Dis. 1996;174(Suppl 2):S134–43.
pubmed: 8843243
doi: 10.1093/infdis/174.Supplement_2.S134
Potterat JJ, Rothenberg RB, Woodhouse DE, Muth JB, Pratts CI, Fogle JS. 2nd. Gonorrhea as a social disease. Sex Transm Dis. 1985;12(1):25–32.
pubmed: 4002091
doi: 10.1097/00007435-198501000-00006
Gesink DC, Sullivan AB, Miller WC, Bernstein KT. Sexually transmitted disease core theory: roles of person, place, and time. Am J Epidemiol. 2011;174(1):81–9.
pubmed: 21540320
doi: 10.1093/aje/kwr035
Ghani AC, Garnett GP. Risks of acquiring and transmitting sexually transmitted diseases in sexual partner networks. Sex Transm Dis. 2000;27(10):579–87.
pubmed: 11099073
doi: 10.1097/00007435-200011000-00006
Jent P, Berger J, Kuhn A, Trautner BW, Atkinson A, Marschall J. Antibiotics for preventing recurrent urinary tract infection: systematic review and Meta-analysis. Open Forum Infect Dis. 2022;9(7):ofac327.
pubmed: 35899289
doi: 10.1093/ofid/ofac327
Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82(9):1052–9.
pubmed: 17803871
doi: 10.4065/82.9.1052
Zalmanovici Trestioreanu A, Fraser A, Gafter-Gvili A, Paul M, Leibovici L. Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev. 2013;2013(10):CD004785.
pubmed: 24163051
Halperin SA, Bortolussi R, Langley JM, Eastwood BJ, De Serres G. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive bordetella pertussis infection. Pediatrics. 1999;104(4):e42.
pubmed: 10506267
doi: 10.1542/peds.104.4.e42
Fleming WL, Wolf MH. The relative prophylactic effectiveness against syphilis of ointments containing calomel in different particle size. Am J Syph Gonorrhea Vener Dis. 1946;30:47–53.
pubmed: 21013301
Brecher EM. Prevention of the sexually transmitted diseases∗. J Sex Res. 1975;11(4):318–28.
doi: 10.1080/00224497509550909
Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (preliminary data): National HIV Surveillance System data reported through June 2021; and preexposure prophylaxis (PrEP) data reported through March 2021. HIV Surveillance Data Table 2021;2(No. 4). http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html . Published October 2021. Accessed February 29, 2024.
Ford N, Irvine C, Shubber Z, Baggaley R, Beanland R, Vitoria M, et al. Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis. AIDS. 2014;28(18):2721–7.
pubmed: 25493598
doi: 10.1097/QAD.0000000000000505
Traeger MW, Cornelisse VJ, Asselin J, Price B, Roth NJ, Willcox J, et al. Association of HIV Preexposure Prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. JAMA. 2019;321(14):1380–90.
pubmed: 30964528
doi: 10.1001/jama.2019.2947
Grant JS, Stafylis C, Celum C, Grennan T, Haire B, Kaldor J, et al. Doxycycline Prophylaxis for bacterial sexually transmitted infections. Clin Infect Dis. 2020;70(6):1247–53.
pubmed: 31504345
doi: 10.1093/cid/ciz866
Peyriere H, Makinson A, Marchandin H, Reynes J. Doxycycline in the management of sexually transmitted infections. J Antimicrob Chemother. 2018;73(3):553–63.
pubmed: 29182717
Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58(2):256–65.
pubmed: 16816396
doi: 10.1093/jac/dkl224
Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988;15(6):355–66.
pubmed: 3072140
doi: 10.2165/00003088-198815060-00001
Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27(9):1329–42.
pubmed: 16291409
doi: 10.1016/j.clinthera.2005.09.005
Tan KR, Magill AJ, Parise ME, Arguin PM, Centers for Disease C. Prevention. Doxycycline for malaria chemoprophylaxis and treatment: report from the CDC expert meeting on malaria chemoprophylaxis. Am J Trop Med Hyg. 2011;84(4):517–31.
pubmed: 21460003
pmcid: 3062442
doi: 10.4269/ajtmh.2011.10-0285
Twartz JC, Shirai A, Selvaraju G, Saunders JP, Huxsoll DL, Groves MG. Doxycycline propylaxis for human scrub typhus. J Infect Dis. 1982;146(6):811–8.
pubmed: 6815282
doi: 10.1093/infdis/146.6.811
Takafuji ET, Kirkpatrick JW, Miller RN, Karwacki JJ, Kelley PW, Gray MR, et al. An efficacy trial of doxycycline chemoprophylaxis against leptospirosis. N Engl J Med. 1984;310(8):497–500.
pubmed: 6363930
doi: 10.1056/NEJM198402233100805
Nadelman RB, Nowakowski J, Fish D, Falco RC, Freeman K, McKenna D, et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med. 2001;345(2):79–84.
pubmed: 11450675
doi: 10.1056/NEJM200107123450201
Geisler WM, Uniyal A, Lee JY, Lensing SY, Johnson S, Perry RC, et al. Azithromycin versus doxycycline for urogenital Chlamydia trachomatis infection. N Engl J Med. 2015;373(26):2512–21.
pubmed: 26699167
pmcid: 4708266
doi: 10.1056/NEJMoa1502599
Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, et al. Sexually Transmitted Infections Treat Guidelines 2021 MMWR Recomm Rep. 2021;70(4):1–187.
pubmed: 34292926
Reimche JL, Clemons AA, Chivukula VL, Joseph SJ, Schmerer MW, Pham CD et al. Genomic analysis of 1710 surveillance-based Neisseria gonorrhoeae isolates from the USA in 2019 identifies predominant strain types and chromosomal antimicrobial-resistance determinants. Microb Genom. 2023;9(5).
Chisholm SA, Neal TJ, Alawattegama AB, Birley HD, Howe RA, Ison CA. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother. 2009;64(2):353–8.
pubmed: 19468025
doi: 10.1093/jac/dkp188
Bolan RK, Beymer MR, Weiss RE, Flynn RP, Leibowitz AA, Klausner JD. Doxycycline prophylaxis to reduce incident syphilis among HIV-infected men who have sex with men who continue to engage in high-risk sex: a randomized, controlled pilot study. Sex Transm Dis. 2015;42(2):98–103.
pubmed: 25585069
pmcid: 4295649
doi: 10.1097/OLQ.0000000000000216
Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018;18(3):308–17.
pubmed: 29229440
doi: 10.1016/S1473-3099(17)30725-9
Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, et al. Postexposure doxycycline to prevent bacterial sexually transmitted infections. N Engl J Med. 2023;388(14):1296–306.
pubmed: 37018493
pmcid: 10140182
doi: 10.1056/NEJMoa2211934
Molina J, Bercot B, Assoumou L, Michele AG, Rubenstein E, Pialoux G, Katlama C, Sugers L, Bebear C, Dupin N, Viard JP, Pavie J, Duvivier C, Ghosn J, Costagliola D, ANRS 174 DOXYVAC: AN OPEN-LABEL RANDOMIZED TRIAL TO PREVENT STIs IN MSM ON PrEP. Presented at the Conference on Retroviruses and Opportunistic Infections. February 19–22 2023, Seattle Washington. Abstract https://www.croiconference.org/abstract/anrs-174-doxyvac-an-open-label-randomized-trial-to-prevent-stis-in-msm-on-prep/ Accessed April 19, 2024. 2023.
Wilson DP, Prestage GP, Gray RT, Hoare A, McCann P, Down I, et al. Chemoprophylaxis is likely to be acceptable and could mitigate syphilis epidemics among populations of gay men. Sex Transm Dis. 2011;38(7):573–9.
pubmed: 21343845
doi: 10.1097/OLQ.0b013e31820e64fd
Traeger M, Mayer KH, Krakower DS, Gitin S, Jenness S, Marcus JL. Potential Impact and Efficiency of Doxy-PEP Among People With or At Risk of HIV. Presented at the Conference on Retroviruses and Opportunistic Infections February 19–22, 2023. Abstract https://www.croiconference.org/abstract/potential-impact-and-efficiency-of-doxy-pep-among-people-with-or-at-risk-of-hiv/ Accessed April 29, 2024.
Bacon O, Kohn RP, Glidden DV, Sankaran M, Levy M, Nguyen TQ, Cohen SE. Doxy-PEP Effectiveness in Men Who Have Sex With Men (MSM) and Transgender Women (TGW) on HIV PrEP. Presented at the Conference on Retroviruses and Opportunistic Infections March 3–6 2024. Abstract https://www.croiconference.org/abstract/doxy-pep-effectiveness-in-men-who-have-sex-with-men-msm-and-transgender-women-tgw-on-hiv-prep/ Accessed APril 29, 2024.
Scott H, Roman J, Spinelli MA, Bena J, Torres TS, Buchbinder SP, Doxycycline PEP. High Uptake and Significant Decline in STIs After Clinical Implementation. Presented at the Conference on Retroviruses and Opportunistic Infections March 3–6 2024. Abstract https://www.croiconference.org/abstract/doxycycline-pep-high-uptake-and-significant-decline-in-stis-after-clinical-implementation/ Accessed April 29, 2024.
Stewart J, Oware K, Donnell D, Violette LR, Odoyo J, Soge OO, et al. Doxycycline Prophylaxis to prevent sexually transmitted infections in women. N Engl J Med. 2023;389(25):2331–40.
pubmed: 38118022
pmcid: 10805625
doi: 10.1056/NEJMoa2304007
Kojima N, Klausner JD. Doxycycline to prevent sexually transmitted infections in women. N Engl J Med. 2024;390(13):1248–9.
pubmed: 38598593
doi: 10.1056/NEJMc2401273
Soge OO, Issema R, Bukusi E, Baeten JM, Mujugira A, Celum C, et al. Predominance of high-level tetracycline-resistant Neisseria gonorrhoeae in Kenya: implications for global implementation of doxycycline postexposure Prophylaxis for Prevention of sexually transmitted infections. Sex Transm Dis. 2023;50(5):317–9.
pubmed: 36728331
pmcid: 10101884
doi: 10.1097/OLQ.0000000000001769
Haaland R, Fountain J, Dinh C, Edwards T, Martin A, Omoyege D, Conway-Washington C, Kelley C, Heneine W. Mucosal Pharmacology of Doxycycline for Bacterial STI Prevention in Men and Women. Presented at the Conference on Retroviruses and Opportunistic Infections February 19–22, 2023. Abstract https://www.croiconference.org/abstract/mucosal-pharmacology-of-doxycycline-for-bacterial-sti-prevention-in-men-and-women/ Accessed April 29, 2024.
Sankaran M, Glidden DV, Kohn RP, Liebi C, Torres TS, Buchbinder SP, Luetkemeyer A, Gandhi M, Havlir D, Nguyen JQ, Scott H, Roman J, Bacon O, Nguyen TQ, Cohen SE. Doxy-PEP Associated With Declines in Chlamydia and Syphilis in MSM and Trans Women in San Francisco. Presented at the Conference on Retroviruses and Opportunistic Infections March 3–6 2024. Abstract https://www.croiconference.org/abstract/doxy-pep-associated-with-declines-in-chlamydia-and-syphilis-in-msm-and-trans-women-in-san-francisco/ Accessed April 29, 2024.
Skidmore R, Kovach R, Walker C, Thomas J, Bradshaw M, Leyden J, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol. 2003;139(4):459–64.
pubmed: 12707093
doi: 10.1001/archderm.139.4.459
Simonart T, Dramaix M, De Maertelaer V. Efficacy of tetracyclines in the treatment of acne vulgaris: a review. Br J Dermatol. 2008;158(2):208–16.
pubmed: 17986300
Chan PA, Le Brazidec DL, Becasen JS, Martin H, Kapadia J, Reno H, et al. Safety of longer-term doxycycline use: a systematic review and Meta-analysis with implications for bacterial sexually transmitted infection Chemoprophylaxis. Sex Transm Dis. 2023;50(11):701–12.
pubmed: 37732844
Sloan B, Scheinfeld N. The use and safety of doxycycline hyclate and other second-generation tetracyclines. Expert Opin Drug Saf. 2008;7(5):571–7.
pubmed: 18759709
doi: 10.1517/14740338.7.5.571
Meijer CA, Stijnen T, Wasser MN, Hamming JF, van Bockel JH, Lindeman JH, et al. Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Ann Intern Med. 2013;159(12):815–23.
pubmed: 24490266
doi: 10.7326/0003-4819-159-12-201312170-00007
Goetze S, Hiernickel C, Elsner P. Phototoxicity of doxycycline: a systematic review on clinical manifestations, frequency, cofactors, and Prevention. Skin Pharmacol Physiol. 2017;30(2):76–80.
pubmed: 28291967
doi: 10.1159/000458761
Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. Drug Saf. 2011;34(10):821–37.
pubmed: 21879777
doi: 10.2165/11592780-000000000-00000
Lochhead J, Elston JS. Doxycycline induced intracranial hypertension. BMJ. 2003;326(7390):641–2.
pubmed: 12649241
pmcid: 1125540
doi: 10.1136/bmj.326.7390.641
Friedman DI, Gordon LK, Egan RA, Jacobson DM, Pomeranz H, Harrison AR, et al. Doxycycline and intracranial hypertension. Neurology. 2004;62(12):2297–9.
pubmed: 15210900
doi: 10.1212/WNL.62.12.2297
Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Report. Atlanta, GA; 2019. https://doi.org/10.15620/cdc:82532 .
Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587–613.
pubmed: 24982323
pmcid: 4135894
doi: 10.1128/CMR.00010-14
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 29th ed. CLSI supplement M100. Wayne, PA: CLSI; 2019.
European Committee on Amtimicrobial Susceptibility Tests. Clinical breakpoints and dosing of antibiotics. https://www.eucast.org/clinical_breakpoints Accessed October 16, 2023.
Wiesner PJ, Holmes KK, Sparling PF, Maness MJ, Bear DM, Gutman LT, et al. Single doses of methacycline and doxycycline for gonorrhea: a cooperative study of the frequency and cause of treatment failure. J Infect Dis. 1973;127(4):461–6.
pubmed: 4632883
doi: 10.1093/infdis/127.4.461
Mortimer TD, Grad YH. A genomic perspective on the Near-term impact of doxycycline post-exposure Prophylaxis on Neisseria gonorrhoeae Antimicrobial Resistance. Clin Infect Dis. 2023;77(5):788–91.
pubmed: 37138444
pmcid: 10495131
doi: 10.1093/cid/ciad279
Whittington WL, Roberts MC, Hale J, Holmes KK. Susceptibilities of Neisseria gonorrhoeae to the glycylcyclines. Antimicrob Agents Chemother. 1995;39(8):1864–5.
pubmed: 7486935
pmcid: 162842
doi: 10.1128/AAC.39.8.1864
La Ruche G, Goubard A, Bercot B, Cambau E, Semaille C, Sednaoui P. Gonococcal infections and emergence of gonococcal decreased susceptibility to cephalosporins in France, 2001 to 2012. Euro Surveill. 2014;19(34).
Batteiger BE, Tu W, Ofner S, Van Der Pol B, Stothard DR, Orr DP, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis. 2010;201(1):42–51.
pubmed: 19929379
doi: 10.1086/648734
Horner PJ. Azithromycin antimicrobial resistance and genital Chlamydia trachomatis infection: duration of therapy may be the key to improving efficacy. Sex Transm Infect. 2012;88(3):154–6.
pubmed: 22416272
doi: 10.1136/sextrans-2011-050385
Bhengraj AR, Vardhan H, Srivastava P, Salhan S, Mittal A. Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India. Chemotherapy. 2010;56(5):371–7.
pubmed: 20938174
doi: 10.1159/000314998
Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis. 2000;181(4):1421–7.
pubmed: 10762573
doi: 10.1086/315372
Jones RB, Van der Pol B, Martin DH, Shepard MK. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J Infect Dis. 1990;162(6):1309–15.
pubmed: 2230260
doi: 10.1093/infdis/162.6.1309
West SK, Moncada J, Munoz B, Mkocha H, Storey P, Hardick J, et al. Is there evidence for resistance of ocular Chlamydia trachomatis to azithromycin after mass treatment for trachoma control? J Infect Dis. 2014;210(1):65–71.
pubmed: 24446528
doi: 10.1093/infdis/jiu046
Pitt R, Alexander S, Ison C, Horner P, Hathorn E, Goold P, et al. Phenotypic antimicrobial susceptibility testing of Chlamydia trachomatis isolates from patients with persistent or successfully treated infections. J Antimicrob Chemother. 2018;73(3):680–6.
pubmed: 29207004
doi: 10.1093/jac/dkx454
Fraser CM, Norris SJ, Weinstock GM, White O, Sutton GG, Dodson R, et al. Complete genome sequence of Treponema pallidum, the syphilis spirochete. Science. 1998;281(5375):375–88.
pubmed: 9665876
doi: 10.1126/science.281.5375.375
Lukehart SA, Godornes C, Molini BJ, Sonnett P, Hopkins S, Mulcahy F, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med. 2004;351(2):154–8.
pubmed: 15247355
doi: 10.1056/NEJMoa040216
Nonaka L, Connell SR, Taylor DE. 16S rRNA mutations that confer tetracycline resistance in Helicobacter pylori decrease drug binding in Escherichia coli ribosomes. J Bacteriol. 2005;187(11):3708–12.
pubmed: 15901694
doi: 10.1128/JB.187.11.3708-3712.2005
Ross JI, Eady EA, Cove JH, Cunliffe WJ. 16S rRNA mutation associated with tetracycline resistance in a gram-positive bacterium. Antimicrob Agents Chemother. 1998;42(7):1702–5.
pubmed: 9661007
doi: 10.1128/AAC.42.7.1702
Sanchez A, Mayslich C, Malet I, Grange PA, Janier M, Saule J, et al. Surveillance of Antibiotic Resistance genes in Treponema Pallidum subspecies Pallidum from patients with early syphilis in France. Acta Derm Venereol. 2020;100(14):adv00221.
pubmed: 32618352
doi: 10.2340/00015555-3589
Giacani L, Ciccarese G, Puga-Salazar C, Dal Conte I, Colli L, Cusini M, et al. Enhanced molecular typing of Treponema pallidum subspecies pallidum strains from 4 Italian hospitals shows geographical differences in strain type heterogeneity, widespread resistance to Macrolides, and lack of mutations Associated with doxycycline resistance. Sex Transm Dis. 2018;45(4):237–42.
pubmed: 29465698
doi: 10.1097/OLQ.0000000000000741
Fernandez-Naval C, Arando M, Espasa M, Anton A, Fernandez-Huerta M, Silgado A, et al. Enhanced molecular typing and macrolide and tetracycline-resistance mutations of Treponema pallidum in Barcelona. Future Microbiol. 2019;14:1099–108.
pubmed: 31512516
doi: 10.2217/fmb-2019-0123
Wu BR, Liu WC, Wu PY, Su YC, Yang SP, Hung CC, et al. Surveillance study of Treponema pallidum harbouring tetracycline resistance mutations in patients with syphilis. Int J Antimicrob Agents. 2014;44(4):370–2.
pubmed: 25130098
doi: 10.1016/j.ijantimicag.2014.06.009
Xiao H, Li Z, Li F, Wen J, Liu D, Du W, et al. Preliminary study of tetracycline resistance genes in Treponema pallidum. J Glob Antimicrob Resist. 2017;9:1–2.
pubmed: 28274848
doi: 10.1016/j.jgar.2017.02.003
Xiao Y, Liu S, Liu Z, Xie Y, Jiang C, Xu M, et al. Molecular Subtyping and Surveillance of Resistance genes in Treponema pallidum DNA from patients with secondary and latent syphilis in Hunan, China. Sex Transm Dis. 2016;43(5):310–6.
pubmed: 27100768
doi: 10.1097/OLQ.0000000000000445
Edmondson DG, Wormser GP, Norris SJ. In Vitro susceptibility of Treponema pallidum subsp. pallidum to doxycycline. Antimicrob Agents Chemother. 2020;64(10).
Chen XS, Yin YP, Wei WH, Wang HC, Peng RR, Zheng HP, et al. High prevalence of azithromycin resistance to Treponema pallidum in geographically different areas in China. Clin Microbiol Infect. 2013;19(10):975–9.
pubmed: 23231450
doi: 10.1111/1469-0691.12098
Anagrius C, Lore B, Jensen JS. Mycoplasma genitalium: prevalence, clinical significance, and transmission. Sex Transm Infect. 2005;81(6):458–62.
pubmed: 16326846
doi: 10.1136/sti.2004.012062
Soni S, Alexander S, Verlander N, Saunders P, Richardson D, Fisher M, et al. The prevalence of urethral and rectal Mycoplasma genitalium and its associations in men who have sex with men attending a genitourinary medicine clinic. Sex Transm Infect. 2010;86(1):21–4.
pubmed: 19843536
doi: 10.1136/sti.2009.038190
Mondeja BA, Couri J, Rodriguez NM, Blanco O, Fernandez C, Jensen JS. Macrolide-resistant Mycoplasma genitalium infections in Cuban patients: an underestimated health problem. BMC Infect Dis. 2018;18(1):601.
pubmed: 30486786
doi: 10.1186/s12879-018-3523-9
Salado-Rasmussen K, Jensen JS. Mycoplasma genitalium testing pattern and macrolide resistance: a Danish nationwide retrospective survey. Clin Infect Dis. 2014;59(1):24–30.
pubmed: 24729494
doi: 10.1093/cid/ciu217
Allan-Blitz LT, Mokany E, Campeau S, Wee R, Shannon C, Klausner JD. Prevalence of Mycoplasma genitalium and azithromycin-resistant infections among remnant clinical specimens, Los Angeles. Sex Transm Dis. 2018;45(9):632–5.
pubmed: 29509566
doi: 10.1097/OLQ.0000000000000829
Barbera MJ, Fernandez-Huerta M, Jensen JS, Caballero E, Andreu A. Mycoplasma genitalium Macrolide and Fluoroquinolone Resistance: prevalence and risk factors among a 2013–2014 cohort of patients in Barcelona, Spain. Sex Transm Dis. 2017;44(8):457–62.
pubmed: 28703723
doi: 10.1097/OLQ.0000000000000631
Gesink D, Racey CS, Seah C, Zittermann S, Mitterni L, Juzkiw J, et al. Mycoplasma genitalium in Toronto, Ont: estimates of prevalence and macrolide resistance. Can Fam Physician. 2016;62(2):e96–101.
pubmed: 27331225
Sweeney EL, Trembizki E, Bletchly C, Bradshaw CS, Menon A, Francis F et al. Levels of Mycoplasma genitalium Antimicrobial Resistance Differ by both region and gender in the state of Queensland, Australia: implications for treatment guidelines. J Clin Microbiol. 2019;57(3).
Bachmann LH, Kirkcaldy RD, Geisler WM, Wiesenfeld HC, Manhart LE, Taylor SN, et al. Prevalence of Mycoplasma genitalium infection, Antimicrobial Resistance mutations, and Symptom Resolution following treatment of Urethritis. Clin Infect Dis. 2020;71(10):e624–32.
pubmed: 32185385
pmcid: 7744987
doi: 10.1093/cid/ciaa293
Vodstrcil LA, Plummer EL, Doyle M, Murray GL, Bodiyabadu K, Jensen JS, et al. Combination therapy for Mycoplasma genitalium, and New insights into the utility of parC mutant detection to Improve Cure. Clin Infect Dis. 2022;75(5):813–23.
pubmed: 34984438
doi: 10.1093/cid/ciab1058
Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55.
doi: 10.1016/S0140-6736(21)02724-0
Truong R, Tang V, Grennan T, Tan DHS. A systematic review of the impacts of oral tetracycline class antibiotics on antimicrobial resistance in normal human flora. JAC Antimicrob Resist. 2022;4(1):dlac009.
pubmed: 35198979
doi: 10.1093/jacamr/dlac009
Furuya R, Onoye Y, Kanayama A, Saika T, Iyoda T, Tatewaki M, et al. Antimicrobial resistance in clinical isolates of Neisseria subflava from the oral cavities of a Japanese population. J Infect Chemother. 2007;13(5):302–4.
pubmed: 17982718
doi: 10.1007/s10156-007-0541-8
Dong HV, Pham LQ, Nguyen HT, Nguyen MXB, Nguyen TV, May F, et al. Decreased Cephalosporin susceptibility of Oropharyngeal Neisseria Species in antibiotic-using men who have sex with men in Hanoi, Vietnam. Clin Infect Dis. 2020;70(6):1169–75.
pubmed: 31049592
doi: 10.1093/cid/ciz365
Laumen JGE, Van Dijck C, Abdellati S, Manoharan-Basil SS, De Baetselier I, Martiny D, et al. Markedly reduced azithromycin and Ceftriaxone susceptibility in Commensal Neisseria species in clinical samples from Belgian men who have sex with men. Clin Infect Dis. 2021;72(2):363–4.
pubmed: 33501961
doi: 10.1093/cid/ciaa565
Lewis DA. Will targeting oropharyngeal gonorrhoea delay the further emergence of drug-resistant Neisseria gonorrhoeae strains? Sex Transm Infect. 2015;91(4):234–7.
pubmed: 25911525
doi: 10.1136/sextrans-2014-051731
Bartlett JG, Bustetter LA, Gorbach SL, Onderdonk AB. Comparative effect of tetracycline and doxycycline on the occurrence of resistant Escherichia coli in the fecal flora. Antimicrob Agents Chemother. 1975;7(1):55–7.
pubmed: 1094945
doi: 10.1128/AAC.7.1.55
Jonsson M, Tunevall G. Selective pressure of tetracyclines on the faecal flora. A comparison between tetracycline and doxycycline. Scand J Infect Dis Suppl. 1976(9):89–93.
Alestig K, Lidin-Janson G. The effect of doxycycline and tetracycline hydrochloride on the aerobic fecal flora, with special reference to Escherichia coli. Scand J Infect Dis. 1975;7(4):265–71.
pubmed: 1108176
doi: 10.3109/inf.1975.7.issue-4.08
Vento TJ, Calvano TP, Cole DW, Mende K, Rini EA, Tully CC, et al. Staphylococcus aureus colonization of healthy military service members in the United States and Afghanistan. BMC Infect Dis. 2013;13:325.
pubmed: 24060181
doi: 10.1186/1471-2334-13-325
Moura IB, Grada A, Spittal W, Clark E, Ewin D, Altringham J, et al. Profiling the effects of systemic antibiotics for Acne, including the narrow-Spectrum Antibiotic Sarecycline, on the human gut microbiota. Front Microbiol. 2022;13:901911.
pubmed: 35711781
doi: 10.3389/fmicb.2022.901911
Angelakis E. Weight gain by gut microbiota manipulation in productive animals. Microb Pathog. 2017;106:162–70.
pubmed: 27836763
doi: 10.1016/j.micpath.2016.11.002
Sadagopan A, Mahmoud A, Begg M, Tarhuni M, Fotso M, Gonzalez NA, et al. Understanding the role of the gut microbiome in diabetes and therapeutics targeting leaky gut: a systematic review. Cureus. 2023;15(7):e41559.
pubmed: 37554593
Alam MZ, Alam Q, Kamal MA, Abuzenadah AM, Haque A. A possible link of gut microbiota alteration in type 2 diabetes and Alzheimer’s disease pathogenicity: an update. CNS Neurol Disord Drug Targets. 2014;13(3):383–90.
pubmed: 24059311
doi: 10.2174/18715273113126660151
Tagliabue A, Elli M. The role of gut microbiota in human obesity: recent findings and future perspectives. Nutr Metab Cardiovasc Dis. 2013;23(3):160–8.
pubmed: 23149072
doi: 10.1016/j.numecd.2012.09.002
Hullar MA, Lampe JW. The gut microbiome and obesity. Nestle Nutr Inst Workshop Ser. 2012;73:67–79.
pubmed: 23128767
doi: 10.1159/000341288
Scher JU, Ubeda C, Artacho A, Attur M, Isaac S, Reddy SM, et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015;67(1):128–39.
pubmed: 25319745
pmcid: 4280348
doi: 10.1002/art.38892
Roggenbuck D, Reinhold D, Baumgart DC, Schierack P, Conrad K, Laass MW. Autoimmunity in Crohn’s Disease-A putative stratification factor of the clinical phenotype. Adv Clin Chem. 2016;77:77–101.
pubmed: 27717419
doi: 10.1016/bs.acc.2016.06.002
Chu V, Glassock A, Donnell D, Grabow C, Ward R, Love C, Cohen SE, Dombrowski JC, Cannon C, Woodworth M, Kelley C, Celum C, Luetkemeyer A, Langelier C, PEP on the Gut Microbiome and Antimicrobial Resistance Gene Expression. Impact of Doxycycline as STI. Presented at the Conference on Retroviruses and Opportunistic Infections March 3–6 2024. Abstract https://www.croiconference.org/abstract/impact-of-doxycycline-as-sti-pep-on-the-gut-microbiome-and-antimicrobial-resistance-gene-expression/ Accessed April 29, 2024.
Traeger M, Krakower DS, Mayer KH, Jenness SM, Marcus JL. National Survey on the Use of Antibiotics as Sexually Transmitted Infection Prophylaxis in the US. Presented at the Conference on Retroviruses and Oppportunistic Infections March 3–6, 2024. Abstract https://www.croiconference.org/abstract/national-survey-on-the-use-of-antibiotics-as-sexually-transmitted-infection-prophylaxis-in-the-us/ Accessed April 29, 2024.
Kohli M, Reid D, Pulford CV, Howarth A, Brown J, Mohammed H, et al. Choice of antibiotics for prophylaxis of bacterial STIs among individuals currently self-sourcing. Sex Transm Infect. 2022;98(2):158.
pubmed: 34873029
doi: 10.1136/sextrans-2021-055310
Pearson WS, Emerson B, Hogben M, Barbee L. Use of doxycycline to prevent sexually transmitted infections according to provider characteristics. Emerg Infect Dis. 2024;30(1):197–9.
pubmed: 38147529
doi: 10.3201/eid3001.231152
Park JJ, Stafylis C, Pearce DD, Taylor J, Little SJ, Kojima N, et al. Interest, concerns, and attitudes among men who have sex with men and Health Care providers toward prophylactic use of doxycycline against Chlamydia trachomatis infections and Syphilis. Sex Transm Dis. 2021;48(9):615–9.
pubmed: 33560092
doi: 10.1097/OLQ.0000000000001395
Bachmann LH, Barbee LA, Chan P, Reno H, Workowski KA, Hoover K, et al. CDC Clinical guidelines on the use of doxycycline postexposure prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024. MMWR Recomm Rep. 2024;73(2):1–8.
pubmed: 38833414
doi: 10.15585/mmwr.rr7302a1
Tiseo K, Huber L, Gilbert M, Robinson TP, Van Boeckel TP. Global trends in Antimicrobial Use in Food animals from 2017 to 2030. Antibiot (Basel). 2020;9(12).
Zhang QQ, Ying GG, Pan CG, Liu YS, Zhao JL. Comprehensive evaluation of antibiotics emission and fate in the river basins of China: source analysis, multimedia modeling, and linkage to bacterial resistance. Environ Sci Technol. 2015;49(11):6772–82.
pubmed: 25961663
doi: 10.1021/acs.est.5b00729
European AIDS, Clinical Society. Guidelines: Version 12.0 October 2023. https://www.eacsociety.org/media/guidelines-12.0.pdf Acccessed April 23, 2024.
Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel. JAMA. 2023;329(1):63–84.
pubmed: 36454551
doi: 10.1001/jama.2022.22246
Cornelisse VJ, Ong JJ, Ryder N, Ooi C, Wong A, Kenchington P, et al. Interim position statement on doxycycline post-exposure prophylaxis (Doxy-PEP) for the prevention of bacterial sexually transmissible infections in Australia and Aotearoa New Zealand - the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). Sex Health. 2023;20(2):99–104.
pubmed: 36927481
doi: 10.1071/SH23011
Kohli M, Medland N, Fifer H, Saunders J. BASHH updated position statement on doxycycline as prophylaxis for sexually transmitted infections. Sex Transm Infect. 2022;98(3):235–6.
pubmed: 35414633
doi: 10.1136/sextrans-2022-055425
World Health Organization. Guidelines for HIV Post-Exposure Prophylaxis. July 22. 2024. https://www.who.int/publications/i/item/9789240095137 Accessed July 30, 2024.
Grennan T, Hull M, Mohammed S, Tattersall T, Edward J, Gupta A, Dennehy MK, Romney M, Morshed M, Zhang W, Guliani S, Trigg J, Lima VD, Montaner JS, Gustafson R. Daily Doxycycline in MSM on PrEP for Prevention of Sexually Transmitted Infections. Presented at the Conference on Retroviruses and Opportunistic Infections March 6–11 2021. Abstract https://www.croiconference.org/abstract/daily-doxycycline-in-msm-on-prep-for-prevention-of-sexually-transmitted-infections/ Accessed April 29, 2024.
Massachusetts State Department of Public Health. Clinical Advisory: Doxycycline Post-Exposure Prophylaxis (PEP) for Prevention of Bacterial Sexually Transmitted Infections (STIs). June 5, 2024. https://www.mass.gov/doc/doxycycline-post-exposure-prophylaxis-pep-for-prevention-of-bacterial-sexually-transmitted-infections-stis-june-5-2024/download Accessed June 21, 2024.